Frontotemporal Dementia (FTD)
19
6
6
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 19 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (19)
A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum
Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)
Digital Measurements of Motor and Voice Functions in FTD
Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
Transcranial Alternating Current Stimulation in Frontotemporal Dementia
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia
Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder
Comprehensive Assessment of Neurodegeneration and Dementia
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
Deep Cervical Lymphaticovenous Anastomosis Surgery for Moderate-to-Advanced Dementia Patients
[18F]ACI-19626 PET in TDP-43 Proteinopathies
Predict to Prevent PGRN Disease
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations